# Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

> **NCT07306949** · PHASE4 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Transthyretin-type Cardiac Amyloidosis

## Interventions

- **DRUG:** Acoramidis

## Key facts

- **NCT ID:** NCT07306949
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306949, "Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07306949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*